Merck (MRK) EBITDA Margin Growth (5y) (2014 - 2026)
Powered by 
Analysis
Merck (MRK) EBITDA Margin Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,767.00 |
| Mar 31, 2026 | -4,468.00 |
| Dec 31, 2025 | 7,183.00 |
| Sep 30, 2025 | 1,576.00 |
| Jun 30, 2025 | 641.00 |
| Mar 31, 2025 | 537.00 |
| Dec 31, 2024 | 6,932.00 |
| Sep 30, 2024 | 437.00 |
| Jun 30, 2024 | 863.00 |
| Mar 31, 2024 | 564.00 |
| Dec 31, 2023 | -992.00 |
| Sep 30, 2023 | 1,290.00 |
| Jun 30, 2023 | -5,381.00 |
| Mar 31, 2023 | 1,531.00 |
| Dec 31, 2022 | 828.00 |
| Sep 30, 2022 | 2,689.00 |
| Jun 30, 2022 | 992.00 |
| Mar 31, 2022 | 1,454.00 |
| Dec 31, 2021 | 3,885.00 |
| Sep 30, 2021 | 900.00 |